ELMMB logo
Facebook logo Twitter logo
MHRA Drug Safety Updates
MHRA Drug Safety Updates


MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

application/pdfDrug safety Update October 2018 PDF.pdf (243KB)11/10/2018Download
 Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in patients in a clinical trial.Ritonavir-containing products:... 
application/pdfMHRA DSU September 2018 PDF.pdf (267KB)25/09/2018Download
 Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers. Xofigo▼ (radium-223-dichloride): new restrictions on use due to increased risk of fracture and... 
application/pdfDrug Safety Update MHRA Aug 2018.pdf (186KB)28/08/2018Download
 Esmya (ulipristal acetate) and risk of serious liver injury: new restrictions to use and requirements for liver function monitoring before, during, and after treatment 
application/pdfDrug Safety Update MHRA July 2018 (249KB)18/07/2018Download
 Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1.Pressurised metered dose inhalers (pMDI): risk of airway... 
application/pdfDrug Safety Update MHRA June 2018.pdf (186KB)03/07/2018Download
 Drug safety Update MHRA June 2018 
application/pdfMHRA Drug Safety Update May 2018.pdf (153KB)04/06/2018Download
 Valproate medicines (Epilim▼, Depakote▼): Pregnancy Prevention Programme materials online. Braltus (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler.  
application/pdfDrug Safety Update MHRA April 2018 (267KB)24/04/2018Download
 Drug Safety Update MHRA April 2018 
application/pdfMHRA DSU March 18-PDF.pdf (274KB)09/03/2018Download
 Drug Safety Update MHRA March 2018. daclizumab, esmya, headlice 
application/pdfDrug Safety Update MHRA February 2018 PDF.pdf (278KB)13/02/2018Download
 Misoprostol vaginal delivery system (Mysodelle): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment. Mycophenolate mofetil, mycophenolic acid: updated... 
application/pdfDrug Safety Update January 2018.pdf (301KB)09/01/2018Download
 Daclizumab (Zinbryta▼) and risk of severe liver injury. Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions. Drug-name confusion: reminder to be vigilant for... 
application/pdfDrug Safety Update MHRA December 2017 (421KB)15/12/2017Download
 Cladribine (Litak, Leustat) for leukaemia, Gadolinium-containing contrast agents, Radium-223 dichloride (Xofigo▼), Eluxadoline (Truberzi ▼): 
application/pdfDrug Safety Update MHRA November 2017 pdf. (357KB)27/11/2017Download
 Gentamicin: potential for histamine-related adverse drug reactions with some batches, Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions, Oral tacrolimus products:... 
Page: [1] [2] [3] [4] [5] [6] [7] [8]